Surface Oncology (Nasdaq:SURF) - Aandelenkoers, Nieuws & Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SURF Overzicht aandelen

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Meer informatie

SURF fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 1 meer risico

Surface Oncology, Inc. Concurrenten

Homology Medicines

NasdaqGS:FIXX

US$54.3m

MediciNova

NasdaqGM:MNOV

US$100.5m

SAB Biotherapeutics

NasdaqCM:SABS

US$28.0m

CollPlant Biotechnologies

NasdaqGM:CLGN

US$48.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Surface Oncology
Historische aandelenkoersen
Huidige aandelenkoers	US$1.07
52 Week Hoogtepunt	US$1.43
52 Week Laag	US$0.56
Bèta	1.75
11 maand verandering	11.47%
3 maanden verandering	38.96%
1 Jaar Verandering	-21.90%
33 jaar verandering	-83.79%
5 jaar verandering	-89.91%
Verandering sinds IPO	-91.97%

Recent nieuws en updates

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

Rendement voor aandeelhouders

	SURF	US Biotechs	US Markt
7D	-0.9%	4.0%	2.0%
1Y	-21.9%	18.0%	32.4%

Rendement versus industrie: SURF presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 18 % opleverde.

Rendement versus markt: SURF presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.4 % opleverde.

Prijsvolatiliteit

Is SURF's price volatile compared to industry and market?
SURF volatility
SURF Average Weekly Movement	8.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SURF is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van SURF is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	35	Rob Ross	www.surfaceoncology.com

Surface Oncology, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Surface Oncology zich tot de beurswaarde?
SURF fundamentele statistieken
Marktkapitalisatie	US$65.08m
Inkomsten(TTM)	-US$92.50m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is SURF overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SURF resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$67.00m
Brutowinst	-US$67.00m
Overige uitgaven	US$25.50m
Inkomsten	-US$92.50m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.52
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SURF op de lange termijn?

Bekijk historische prestaties en vergelijking

This company has been acquired

SURF Overzicht aandelen

Risicoanalyse

Surface Oncology, Inc. Concurrenten

NasdaqGS:FIXX

US$54.3m

NasdaqGM:MNOV

US$100.5m

NasdaqCM:SABS

US$28.0m

NasdaqGM:CLGN

US$48.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Price target decreased to US$5.25

Consensus forecasts updated

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Consensus revenue estimates increase by 46%

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Price target decreased to US$13.00

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Consensus forecasts updated

Price target decreased to US$14.75

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$21.0m

Investor sentiment deteriorated over the past week

Surface Oncology: A Diverse, But Early Pipeline

Chairman of the Board exercised options and sold US$862k worth of stock

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$28.1m

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology EPS beats by $0.04, beats on revenue

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Analysts lower revenue estimates to US$18.8m

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors